Aktis Oncology (NASDAQ:AKTS) Director Ken Herrmann Sells 4,856 Shares

Aktis Oncology (NASDAQ:AKTS) Director Ken Herrmann sold 4,856 shares of the business’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the completion of the transaction, the director directly owned 3,506 shares in the company, valued at approximately $86,107.36. This represents a 58.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Aktis Oncology Price Performance

Shares of NASDAQ:AKTS opened at $22.97 on Wednesday. Aktis Oncology has a 1 year low of $14.72 and a 1 year high of $34.19. The company has a market cap of $1.23 billion and a P/E ratio of -60.45. The company has a fifty day simple moving average of $24.07.

Aktis Oncology (NASDAQ:AKTS) last released its earnings results on Monday, May 11th. The technology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The firm had revenue of $3.23 million during the quarter, compared to the consensus estimate of $2.23 million. On average, sell-side analysts forecast that Aktis Oncology will post -1.64 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on AKTS shares. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Wall Street Zen cut shares of Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright increased their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. William Blair began coverage on Aktis Oncology in a research report on Wednesday, April 29th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. boosted their target price on Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Aktis Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $34.60.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.